Roivant Sciences
ROIV
338 hedge funds and large institutions have $5.8B invested in Roivant Sciences in 2025 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 115 increasing their positions, 109 reducing their positions, and 35 closing their positions.
690% more call options, than puts
Call options by funds: $87.5M | Put options by funds: $11.1M
74% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 35
8% more funds holding
Funds holding: 313 → 338 (+25)
6% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 109
3% more capital invested
Capital invested by funds: $5.63B → $5.8B (+$172M)
2.47% less ownership
Funds ownership: 78.15% → 75.68% (-2.5%)
28% less funds holding in top 10
Funds holding in top 10: 18 → 13 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$95M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$57.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.7M |
| 4 |
PA
Perceptive Advisors
New York
|
+$36.1M |
| 5 |
O
OrbiMed
New York
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$395M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$128M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$88.8M |
| 4 |
TCIM
TOMS Capital Investment Management
New York
|
-$44.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$43M |
ROIV Hedge Fund Activity: Q2 2025 in Review
338 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q2 2025, worth a combined $5.8B — up 3.1% from $5.63B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new ROIV positions and 35 closed out — a net gain of 26 holders — while 115 added to existing stakes and 109 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $95M. The largest seller was QVT Financial, cutting an estimated $395M.
- 338 institutional investors held Roivant Sciences (ROIV) as of Q2 2025, up from 313 in Q1 2025.
- Funds reported $5.8B of Roivant Sciences stock for Q2 2025, up 3.1% quarter-over-quarter.
- 61 funds opened new Roivant Sciences positions in Q2 2025 and 35 closed out, a net change of +26 holders.
- The largest Roivant Sciences buyer in Q2 2025 was Morgan Stanley, an estimated $95M added.
- The largest Roivant Sciences seller in Q2 2025 was QVT Financial, an estimated $395M sold.
Based on aggregated 13F filings for Q2 2025.